A new trading day began on Monday, with Akero Therapeutics Inc (NASDAQ: AKRO) stock price down -5.64% from the previous day of trading, before settling in for the closing price of $54.21. AKRO’s price has ranged from $17.84 to $58.40 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Meanwhile, its annual earnings per share averaged -37.36%. With a float of $62.72 million, this company’s outstanding shares have now reached $69.61 million.
Let’s look at the performance matrix of the company that is accounted for 56 employees. In terms of profitability, gross margin is 98.59%, operating margin of -94813.73%, and the pretax margin is -83528.87%.
Akero Therapeutics Inc (AKRO) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Akero Therapeutics Inc is 16.52%, while institutional ownership is 91.17%. The most recent insider transaction that took place on Jan 30 ’25, was worth 9,600,000. In this transaction Director of this company bought 200,000 shares at a rate of $48.00, taking the stock ownership to the 1,000,000 shares. Before that another transaction happened on Feb 05 ’25, when Company’s Chief Scientific Officer sold 18,750 for $56.51, making the entire transaction worth $1,059,630. This insider now owns 170,237 shares in total.
Akero Therapeutics Inc (AKRO) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.11 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -37.36% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -19.08% during the next five years compared to 1.03% growth over the previous five years of trading.
Akero Therapeutics Inc (NASDAQ: AKRO) Trading Performance Indicators
Here are Akero Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 17.25.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.75, a number that is poised to hit -1.16 in the next quarter and is forecasted to reach -4.77 in one year’s time.
Technical Analysis of Akero Therapeutics Inc (AKRO)
Akero Therapeutics Inc (NASDAQ: AKRO) saw its 5-day average volume 1.05 million, a negative change from its year-to-date volume of 1.9 million. As of the previous 9 days, the stock’s Stochastic %D was 41.36%. Additionally, its Average True Range was 3.55.
During the past 100 days, Akero Therapeutics Inc’s (AKRO) raw stochastic average was set at 80.44%, which indicates a significant increase from 78.49% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 280.75% in the past 14 days, which was higher than the 119.63% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $33.83, while its 200-day Moving Average is $27.76. Nevertheless, the first resistance level for the watch stands at $54.29 in the near term. At $57.42, the stock is likely to face the second major resistance level. The third major resistance level sits at $59.04. If the price goes on to break the first support level at $49.54, it is likely to go to the next support level at $47.92. Assuming the price breaks the second support level, the third support level stands at $44.79.
Akero Therapeutics Inc (NASDAQ: AKRO) Key Stats
With a market capitalization of 3.84 billion, the company has a total of 69,799K Shares Outstanding. Currently, annual sales are 0 K while annual income is -151,760 K. The company’s previous quarter sales were 0 K while its latest quarter income was -72,710 K.
